Inovio Pharmaceuticals (INO) stock price, revenue, and financials

Inovio Pharmaceuticals market cap is $2 b, and annual revenue was $4.11 m in FY 2019

$2 B

INO Mkt cap, 16-Oct-2020

$267.2 K

Inovio Pharmaceuticals Revenue Q2, 2020
Inovio Pharmaceuticals Net income (Q2, 2020)-129.2 M
Inovio Pharmaceuticals EBIT (Q2, 2020)-33.2 M
Inovio Pharmaceuticals Cash, 30-Jun-2020215.4 M
Inovio Pharmaceuticals EV1.8 B

Inovio Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.4m2.6m1.7m436.1k854.7k785.6k9.5m2.4m3.8m1.8m5.2m5.3m24.2m8.1m6.2m12.5m10.4m20.4m2.6m1.5m24.4m2.0m2.8m135.7k866.9k1.3m267.2k

R&D expense

4.5m7.0m4.0m4.5m5.0m4.4m5.4m8.2m9.6m7.0m9.4m16.7m16.1m18.2m19.6m27.0m24.5m23.9m25.5m24.6m22.5m21.9m24.4m22.5m19.1m19.1m22.4m

General and administrative expense

3.1m2.3m2.5m2.7m2.7m3.0m3.3m4.1m4.3m3.2m4.1m4.7m4.4m5.4m5.8m5.8m7.8m6.2m6.3m9.7m7.2m6.8m7.0m5.9m5.7m7.4m11.1m

Operating expense total

7.6m9.3m6.5m7.2m7.6m7.5m8.7m12.4m14.0m10.2m13.5m21.4m20.5m23.6m25.4m32.7m32.3m30.0m31.8m34.3m29.7m28.6m31.4m28.3m24.8m26.6m33.4m

EBIT

(5.1m)(6.3m)(4.2m)(6.8m)(6.3m)(5.7m)765.6k(10.0m)(10.2m)(8.3m)(8.4m)(15.1m)3.7m(15.5m)(18.2m)(20.2m)(21.9m)(9.6m)(29.2m)(32.7m)(5.2m)(26.6m)(28.5m)(28.2m)(24.0m)(25.2m)(33.2m)

EBIT margin, %

(212%)(240%)(247%)(1557%)(736%)(722%)8%(424%)(267%)(453%)(162%)(286%)15%(191%)(294%)(161%)(211%)(47%)(1104%)(2141%)(21%)(1332%)(1008%)(20786%)(2763%)(1901%)(12419%)

Interest expense

7.8k5.7k66.6k

Interest income

31.5k41.0k37.0k37.4k46.8k52.1k69.0k97.2k138.3k146.3k215.0k333.1k341.1k391.6k340.3k300.0k463.3k312.5k396.7k381.0k755.3k637.4k416.6k1.1m

Investment income

(901.8k)

Pre tax profit

3.8m(20.8m)(30.2m)(6.6m)(25.0m)(29.4m)(29.7m)(23.5m)(33.1m)(128.3m)

Income tax expense

(1.8m)2.2m(62.8k)(106.8k)

Net Income

(2.8m)(4.5m)(8.3m)(4.1m)(6.6m)(10.9m)(30.9m)(10.8m)(10.7m)(7.2m)(10.6m)(6.2m)5.6m(8.0m)(18.7m)(20.8m)(23.1m)(9.5m)(34.1m)(32.4m)(6.6m)(25.0m)(29.2m)(29.4m)(23.1m)(33.1m)(129.2m)

Inovio Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

17.4m33.7m40.5m57.6m19.1m23.8m23.7m22.2m

Accounts Receivable

467.9k3.3m2.8m7.3m15.8m6.0m3.3m700.1k

Prepaid Expenses

746.0k637.4k798.0k917.3k2.6m1.4m1.6m

Inventories

1.7m

Current Assets

31.9m58.7m98.9m171.9m124.6m138.4m87.8m94.2m

PP&E

295.8k2.9m4.6m7.3m18.3m15.9m12.8m

Goodwill

10.1m10.1m10.1m10.1m10.5m10.5m10.5m10.5m

Total Assets

61.1m88.3m131.8m213.8m173.7m187.2m131.1m144.0m

Accounts Payable

4.3m5.4m6.4m13.1m19.6m23.3m23.1m18.2m

Short-term debt

2.1m

Current Liabilities

11.0m29.0m14.0m31.5m43.8m35.4m35.3m32.0m

Long-term debt

20.4m

Total Debt

22.5m

Total Liabilities

13.2m35.4m20.2m37.9m50.3m44.8m44.1m138.5m

Common Stock

135.0k210.3k60.7k72.2k90.4k97.2k101.4k

Preferred Stock

Additional Paid-in Capital

257.2m348.1m443.3m534.0m556.7m665.8m707.8m742.6m

Retained Earnings

(210.1m)(295.8m)(331.9m)(361.1m)(434.8m)(523.4m)(620.4m)(739.8m)

Total Equity

47.9m52.9m111.5m175.9m123.4m142.5m87.0m5.4m

Financial Leverage

1.3 x1.7 x1.2 x1.2 x1.4 x1.3 x1.5 x26.6 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

30.6m25.3m11.1m6.0m4.6m10.4m33.1m98.8m88.5m70.7m26.1m70.3m85.5m41.6m28.5m23.3m22.9m23.9m23.3m37.5m15.1m19.4m20.8m19.7m15.9m158.4m215.4m

Accounts Receivable

347.8k426.9k876.7k432.1k481.4k540.3k10.6m2.7m2.9m1.6m3.3m5.6m11.0m11.2m10.4m17.5m9.9m7.5m6.2m5.1m1.7m2.8m2.8m130.2k776.3k641.6k3.5m

Prepaid Expenses

822.2k866.0k760.7k598.5k487.7k710.3k471.9k673.9k542.0k657.7k551.3k1.3m1.1m1.2m1.4m4.2m4.9m4.5m2.0m1.8m1.6m1.4m2.3m1.7m2.5m4.6m

Current Assets

38.6m32.7m26.9m21.3m16.9m25.5m57.9m121.7m112.9m104.6m87.3m162.1m184.1m160.6m148.0m140.2m106.8m106.9m154.6m123.8m101.8m93.6m134.9m110.5m98.8m275.5m382.1m

PP&E

306.1k288.9k355.3k421.5k391.5k348.1k2.3m4.5m4.6m4.9m5.5m6.5m8.4m8.7m9.0m9.8m15.0m18.5m17.5m16.9m16.2m15.2m14.3m13.5m12.1m11.3m

Goodwill

10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.1m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m10.5m

Total Assets

67.9m63.3m55.4m48.6m44.5m51.0m88.0m151.7m142.2m134.5m117.9m201.7m230.8m211.3m204.0m194.5m153.3m158.9m203.7m173.7m148.9m140.7m191.2m165.1m151.5m338.9m443.2m

Accounts Payable

3.2m3.3m3.3m3.5m3.1m3.3m4.0m5.3m5.3m4.7m4.4m6.1m10.5m12.1m12.7m16.2m14.5m16.5m22.5m15.8m12.6m17.3m15.6m13.4m9.8m11.0m17.2m

Short-term debt

11.2m11.7m13.0m2.1m2.2m

Current Liabilities

9.9m9.7m13.0m10.2m11.3m19.1m20.4m15.6m11.6m8.9m8.2m14.5m18.3m33.4m35.5m41.4m40.0m27.4m33.4m51.4m28.4m28.0m27.4m24.1m19.5m32.3m38.0m

Long-term debt

82.6m84.2m21.0m

Total Debt

11.2m11.7m13.0m82.6m62.8m21.0m2.1m2.2m

Total Liabilities

12.3m12.0m15.1m12.2m13.2m21.3m25.8m22.5m19.9m17.5m14.4m20.7m37.4m40.1m41.9m47.6m47.4m35.3m41.6m60.6m37.4m37.0m110.2m108.6m115.4m151.1m256.8m

Common Stock

127.3k127.3k135.0k135.0k137.1k180.1k207.6k240.1k60.3k60.5k60.7k71.8k72.2k72.3k73.5k74.0k74.6k77.6k90.3k90.7k91.5k94.5k97.9k98.6k99.0k145.9k158.8k

Preferred Stock

Additional Paid-in Capital

255.0m255.2m257.8m258.1m259.6m278.6m342.0m435.2m439.1m441.3m445.7m529.6m532.6m537.1m546.3m552.8m563.2m589.9m663.2m668.8m674.0m690.9m727.2m731.8m735.0m958.0m1.1b

Retained Earnings

(200.1m)(204.6m)(218.3m)(222.5m)(229.1m)(249.5m)(280.3m)(306.6m)(317.3m)(324.5m)(342.5m)(348.7m)(343.1m)(369.1m)(387.8m)(408.6m)(458.2m)(467.7m)(501.9m)(555.5m)(562.1m)(587.1m)(649.6m)(679.0m)(702.1m)(772.3m)(901.0m)

Total Equity

55.6m51.3m40.2m36.4m31.3m29.7m62.2m122.3m117.0m103.4m181.0m193.4m171.2m162.1m147.0m105.9m123.5m162.1m113.1m111.5m103.7m81.0m56.5m36.1m187.9m186.4m

Debt to Equity Ratio

0.3 x0.4 x0.4 x1 x1.1 x

Debt to Assets Ratio

0.2 x0.3 x0.3 x0.4 x0.4 x

Financial Leverage

1.2 x1.2 x1.4 x1.3 x1.4 x1.7 x1.4 x1.2 x1.1 x1.1 x1.1 x1.2 x1.2 x1.3 x1.3 x1.4 x1.3 x1.3 x1.5 x1.3 x1.4 x2.4 x2.9 x4.2 x1.8 x2.4 x

Inovio Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(15.3m)(66.1m)(36.1m)(29.1m)(73.7m)(88.2m)(97.0m)(120.6m)

Depreciation and Amortization

142.2k2.1m1.6m1.9m3.1m3.5m5.0m4.7m

Accounts Receivable

(435.0k)(2.5m)499.2k(4.5m)(8.5m)9.8m2.7m2.6m

Accounts Payable

1.8m2.2m1.5m6.5m6.4m2.8m550.4k(4.3m)

Cash From Operating Activities

(19.8m)(15.4m)(29.8m)(12.4m)(62.6m)(63.2m)(73.6m)(97.9m)

Purchases of PP&E

(161.2k)(176.9k)(1.4m)(2.8m)(2.7m)(10.3m)(2.1m)(987.9k)

Cash From Investing Activities

(10.9m)(9.2m)(35.8m)(54.8m)16.3m(27.8m)42.4m(9.0m)

Dividends Paid

(149.6k)(149.6k)

Cash From Financing Activities

28.0m52.7m72.5m84.4m7.8m95.7m31.0m105.4m

Net Change in Cash

(2.6m)28.1m6.8m17.1m(38.5m)4.7m(92.9k)(1.5m)

Interest Paid

2.7m

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.2m)(9.8m)(8.3m)(12.4m)(19.0m)(19.7m)(50.6m)(10.8m)(21.5m)(28.7m)(10.6m)(16.7m)(11.2m)(8.0m)(26.7m)(47.5m)(23.1m)(32.6m)(66.7m)(32.4m)(39.0m)(64.0m)(29.3m)(58.9m)(82.4m)(33.1m)(162.3m)

Depreciation and Amortization

66.6k101.9k36.8k77.2k124.1k81.0k1.5m721.7k1.1m437.5k894.0k1.4m597.4k1.4m1.3m928.6k1.0m3.0m1.3m2.6m2.8m930.9k2.4m3.5m946.3k1.6m

Accounts Receivable

(314.9k)(394.1k)(408.8k)35.8k(13.5k)290.1k(9.7m)424.9k1.7m(495.4k)(2.8m)(8.2m)(3.8m)(3.0m)(10.1m)6.0m8.3m9.6m855.4k4.3m3.2m533.1k3.2m2.5m58.4k(2.8m)

Accounts Payable

80.5k513.9k(1.3m)(695.0k)(860.2k)481.3k792.1k24.5k(970.9k)(2.7m)34.0k3.3m(1.6m)(247.0k)2.9m(5.6m)(4.3m)1.1m(6.4m)(9.4m)(4.9m)(7.0m)(9.2m)(12.8m)(7.2m)(732.8k)

Cash From Operating Activities

(10.0m)(15.2m)(5.4m)(10.8m)(16.8m)(10.6m)(16.3m)(13.7m)(21.7m)(12.1m)(21.1m)(5.7m)(15.7m)(29.0m)(47.7m)(15.2m)(31.9m)(49.3m)(12.6m)(31.6m)(56.3m)(32.5m)(56.4m)(84.1m)(25.5m)(52.6m)

Purchases of PP&E

(96.0k)(114.0k)(96.3k)(202.9k)(219.9k)(66.1k)(250.6k)(887.2k)(1.2m)(526.9k)(1.2m)(2.0m)(681.1k)(2.2m)(2.7m)(789.3k)(5.8m)(9.4m)(1.2m)(1.6m)(1.7m)(658.7k)(739.8k)(873.5k)(141.0k)(176.5k)

Cash From Investing Activities

(3.8m)(3.8m)(784.3k)(646.6k)2.8m(4.3m)(4.5m)(2.3m)(12.6m)(2.3m)(31.6m)(33.6m)(338.2k)(2.7m)6.4m18.2m11.7m(42.4m)26.8m20.8m35.2m(49.3m)(27.7m)(19.5m)(51.8m)(94.2m)

Cash From Financing Activities

24.3m24.3m1.2m19.6m48.2m70.8m71.3m82.5m84.2m69.5k2.5m6.9m826.4k24.9m95.8m(506.4k)2.1m16.6m78.9m80.2m95.8m213.5m340.0m

Net Change in Cash

10.6m5.3m(6.2m)(11.4m)(12.8m)4.7m27.4m54.8m36.9m(14.4m)29.8m44.9m(16.0m)(29.2m)(34.4m)3.8m4.7m4.1m13.7m(8.7m)(4.4m)(2.9m)(4.0m)(7.8m)136.3m193.2m

Interest Paid

2.7m2.6m2.6m

Inovio Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.2 x

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620

Inovio Pharmaceuticals Employee Rating

3.518 votes
Culture & Values
3.2
Work/Life Balance
3.4
Senior Management
3.2
Salary & Benefits
3.3
Career Opportunities
3
Source